Antibacterial efficacy of phages against Pseudomonas aeruginosa infections in mice and Drosophila melanogaster

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 6, 2009, Pages 2469-2474

  Heo, Yun Jeong ^a   Lee, Yu Rim ^a   Jung, Hyun Hee ^a   Lee, Jungeun ^b   Ko, GwangPyo ^b   Cho, You Hee ^a  

^a Sogang University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIOPHAGE MPK1; BACTERIOPHAGE MPK6; BACTERIOPHAGE RECEPTOR; LIPOPOLYSACCHARIDE; POLYSACCHARIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL PERITONITIS; BACTERICIDAL ACTIVITY; BACTERIOPHAGE; BACTERIUM PILUS; CELL LYSATE; CONTROLLED STUDY; DROSOPHILA MELANOGASTER; DRUG EFFICACY; FEMALE; MORTALITY; MOUSE; NONHUMAN; PHAGE THERAPY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RNA PHAGE; SEPSIS; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; DISEASE MODELS, ANIMAL; DROSOPHILA MELANOGASTER; FEMALE; MICE; MICE, INBRED ICR; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS PHAGES; RECEPTORS, VIRUS;

EID: 67049086922     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01646-08     Document Type: Article

References (33)

1. Ackermann, H. W. 2001. Frequency of morphological phage descriptions in the year 2000. Brief review. Arch. Virol. 146:843-857.
2. Ackermann, H. W. 1998. Tailed bacteriophages: the order Caudovirales. Adv. Virus Res. 51:135-201.
3. Alisky, J., K. Iczkowski, A. Rapoport, and N. Troitsky. 1998. Bacteriophages show promise as antimicrobial agents. J. Infect. 36:5-15. (Pubitemid 128645619)
4. Aronoff, S. C., M. M. Olson, M. W. Gauderer, M. R. Jacobs, J. L. Blumer, and R. J. Izant, Jr. 1987. Pseudomonas aeruginosa as a primary pathogen in children with bacterial peritonitis. J. Pediatr. Surg. 22:861-864.
5. Barekzi, N. A., K. A. Poelstra, A. G. Felts, I. A. Rojas, J. B. Slunt, and D. W. Grainger. 1999. Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa peritonitis in a murine model. Antimicrob. Agents Chemother. 43:1609-1615.
6. Bradley, D. E. 1973. The length of the filamentous Pseudomonas aeruginosa bacteriophage Pf. J. Gen. Virol. 20:249-252.
7. Bradley, D. E. 1973. A pilus-dependent Pseudomonas aeruginosa bacteriophage with a long noncontractile tail. Virology 51:489-492.
8. Bradley, D. E. 1967. Ultrastructure of bacteriophage and bacteriocins. Bacteriol. Rev. 31:230-314.
9. Breger, J., B. B. Fuchs, G. Aperis, T. I. Moy, F. M. Ausubel, and E. Mylonakis. 2007. Antifungal chemical compounds identified using a C. elegans pathogenicity assay. PLoS Pathog. 3:e18.
10. Hagens, S., A. Habel, U. von Ahsen, A. von Gabain, and U. Blasi. 2004. Therapy of experimental Pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob. Agents Chemother. 48:3817-3822.
11. Heo, Y.-J., I.-Y. Chung, K. B. Choi, and Y.-H. Cho. 2007. R-type pyocin is required for competitive growth advantage between Pseudomonas aeruginosa strains. J. Microbiol. Biotechnol. 17:180-185.
12. Heo, Y.-J., I.-Y. Chung, K. B. Choi, G. W. Lau, and Y.-H. Cho. 2007. Genome sequence comparison and superinfection between two related Pseudomonas aeruginosa phages, D3112 and MP22. Microbiology 153:2885-2895.
13. Jarrell, K. F., and A. M. Kropinski. 1981. Pseudomonas aeruginosa bacteriophage φPLS27-lipopolysaccharide interactions. J. Virol. 40:411-420.
14. Johnson, C. C., J. Baldessarre, and M. E. Levison. 1997. Peritonitis: update on pathophysiology, clinical manifestations, and management. Clin. Infect. Dis. 24:1035-1045. (Quiz, 24:1046-1047.)
15. Juergensen, P. H., F. O. Finkelstein, R. Brennan, S. Santacroce, and M. J. Ahern. 1988. Pseudomonas peritonitis associated with continuous ambulatory peritoneal dialysis: a six-year study. Am. J. Kidney Dis. 11:413-417.
16. Kim, S.-H., S.-Y. Park, Y.-J. Heo, and Y.-H. Cho. 2008. Drosophila melanogaster-based screening for multihost virulence factors of Pseudomonas aeruginosa PA14 and identification of a virulence-attenuating factor, HudA. Infect. Immun. 76:4152-4162.
17. Krothapalli, R., W. B. Duffy, C. Lacke, W. Payne, H. Patel, V. Perez, and H. O. Senekjian. 1982. Pseudomonas peritonitis and continuous ambulatory peritoneal dialysis. Arch. Intern. Med. 142:1862-1863.
18. Lee, J.-S., Y.-J. Heo, J. K. Lee, and Y.-H. Cho. 2005. KatA, the major catalase, is critical for osmoprotection and virulence in Pseudomonas aeruginosa PA14. Infect. Immun. 73:4399-4403.
19. Matsuzaki, S., M. Rashel, J. Uchiyama, S. Sakurai, T. Ujihara, M. Kuroda, M. Ikeuchi, T. Tani, M. Fujieda, H. Wakiguchi, and S. Imai. 2005. Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J. Infect. Chemother. 11:211-219.
20. McVay, C. S., M. Velasquez, and J. A. Fralick. 2007. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob. Agents Chemother. 51:1934-1938.
21. Moy, T. I., A. R. Ball, Z. Anklesaria, G. Casadei, K. Lewis, and F. M. Ausubel. 2006. Identification of novel antimicrobials using a live-animal infection model. Proc. Natl. Acad. Sci. USA 103:10414-10419.
22. Pruitt, B. A., Jr., A. T. McManus, S. H. Kim, and C. W. Goodwin. 1998. Burn wound infections: current status. World J. Surg. 22:135-145.
23. Rosenfeld, M., B. W. Ramsey, and R. L. Gibson. 2003. Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management. Curr. Opin. Pulm. Med. 9:492-497.
24. Scholl, D., and D. W. Martin, Jr. 2008. Antibacterial efficacy of R-type pyocins towards Pseudomonas aeruginosa in a murine peritonitis model. Antimicrob. Agents Chemother. 52:1647-1652.
25. Slopek, S., B. Weber-Dabrowska, M. Dabrowski, and A. Kucharewicz- Krukowska. 1987. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch. Immunol. Ther. Exp. (Warsz.) 35:569-583.
26. Soothill, J., C. Hawkins, E. Anggard, and D. Harper. 2004. Therapeutic use of bacteriophages. Lancet Infect. Dis. 4:544-545.
27. Speert, D. P., M. E. Campbell, D. A. Henry, R. Milner, F. Taha, A. Gravelle, A. G. Davidson, L. T. Wong, and E. Mahenthiralingam. 2002. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis in British Columbia, Canada. Am. J. Respir. Crit. Care Med. 166:988-993.
28. Steinstraesser, L., Y. Oezdogan, S. C. Wang, and H. U. Steinau. 2004. Host defense peptides in burns. Burns 30:619-627. (Pubitemid 39328196)
29. Summers, W. C. 2001. Bacteriophage therapy. Annu. Rev. Microbiol. 55:437-451.
30. Summers, W. C. 1999. Felix d'Herelle and the origins of molecular biology. Yale University Press, New Haven, CT.
31. Watanabe, R., T. Matsumoto, G. Sano, Y. Ishii, K. Tateda, Y. Sumiyama, J. Uchiyama, S. Sakurai, S. Matsuzaki, S. Imai, and K. Yamaguchi. 2007. Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob. Agents Chemother. 51:446-452.
32. Weinstein, W. M., A. B. Onderdonk, J. G. Bartlett, and S. L. Gorbach. 1974. Experimental intra-abdominal abscesses in rats: development of an experimental model. Infect. Immun. 10:1250-1255.
33. Yokota, S., T. Hayashi, and H. Matsumoto. 1994. Identification of the lipopolysaccharide core region as the receptor site for a cytotoxin-converting phage, φCTX, of Pseudomonas aeruginosa. J. Bacteriol. 176:5262-5269. (Pubitemid 24273511)